FDA grants orphan drug designation for RP treatment

The FDA has granted orphan drug designation for chemically induced photoreceptor-like cells to treat retinitis pigmentosa (RP), according to a press release from CiRC Biosciences.

The technology “enables direct chemical transdifferentiation of fibroblasts into other cell types using a cocktail of small molecules in a chemical conversion process that takes less than 2 weeks,” the release said.


Click here to read the rest of the article.


Printed in Ocular Surgery News | March 15, 2021